Sign in
CompletedNo phase

Evaluation of DiaSorin LIAISON® PTX3 (Long Pentraxin 3) Assay in Patients With Pneumonia

Key facts

Who runs it
Diasorin Italia S.p.A.
Where
Italy2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
281 people enrolled
Started
20 Sept 2021
Ended
29 Mar 2024
Type of study
Observational
Treatments tested
  • PTX3 assay
Record updated
8 July 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Subjects willing and able to sign the approved Informed Consent form in accordance with international and national regulations
  • Patients diagnosed with pneumonia, either CAP, HAP, VAP
  • Collection of plasma samples within 24 hours from pneumonia diagnosis (for CAP diagnosis is usually made at ED presentation and for HAP and VAP diagnosis is made during hospital stay)
  • K2 EDTA plasma samples dedicated to the study have a minimum volume of 3 mL

Who cannot take part

  • Patients who are currently pregnant
  • Samples collected and/or stored in an inappropriate way

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

LIAISON® PTX3 is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of Long Pentraxin 3 (PTX3) in human plasma samples.

Read full original descriptionShow less

LIAISON® PTX3, in conjunction with clinical evaluation and other laboratory findings, may serve as an aid in the determination of disease severity and prognosis of patients with community-acquired (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).

Treatments tested

  • PTX3 assay

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
8 July 2024